Gufic Biosciences trades jubilantly on getting nod to manufacture, sell, distribute Isavuconazonium Sulfate API
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Gufic Biosciences is currently trading at Rs. 276.60, up by 28.75 points or 11.60% from its previous closing of Rs. 247.85 on the BSE.
The scrip opened at Rs. 257.30 and has touched a high and low of Rs. 283.50 and Rs. 251.90 respectively. So far 166028 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 283.50 on 12-Apr-2022 and a 52 week low of Rs. 107.60 on 12-Apr-2021.
Last one week high and low of the scrip stood at Rs. 283.50 and Rs. 246.65 respectively. The current market cap of the company is Rs. 2626.23 crore.
The promoters holding in the company stood at 75.48%, while Institutions and Non-Institutions held 2.88% and 21.64% respectively.
Gufic Biosciences has received permission from Central Licensing Approving Authority, Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare for manufacture, sale and distribution of Isavuconazonium Sulfate API and finished formulation Isavuconazole for Injection 200 mg/vial. Isavuconazole for Injection 200 mg/vial is indicated for the treatment of patients having 18 years of age and older for the treatment of Invasive Aspergillosis and Invasive Mucormycosis.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
